<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04982029</url>
  </required_header>
  <id_info>
    <org_study_id>2021P001829</org_study_id>
    <nct_id>NCT04982029</nct_id>
  </id_info>
  <brief_title>Cannabidiol on Reward- and Stress-related Neurocognitive Processes in Individuals With Opioid Use Disorder</brief_title>
  <official_title>Cannabidiol on reward-and Stress-related Neurocognitive Processes in Individuals With Opioid Use Disorder: A Double-blind, Placebo-controlled, Cross-over Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Harvard Medical School (HMS and HSDM)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the impact of cannabidiol on reward- and&#xD;
      stress-related neurocognitive processes among individuals with opioid use disorder on&#xD;
      buprenorphine or methadone treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Individuals with opioid use disorder (OUD) demonstrate reward- and stress-related&#xD;
      neurocognitive changes compared to individuals without OUD, including cravings for opioids in&#xD;
      response to exposure to triggers, tendency to make impulsive and disadvantageous decisions,&#xD;
      and a strong attentional bias towards drug-related cues. Together, these deficits are&#xD;
      significant contributors to relapse and discontinuation of treatment. Cannabidiol (CBD) has&#xD;
      been shown to impact some of these cognitive deficits but studies of CBD among individuals&#xD;
      with OUD are mostly lacking. Therefore, this study aims to answer whether CBD has any impact&#xD;
      on reward-related neurocognitive deficits in individuals with OUD. If successful, this line&#xD;
      of research will lay the groundwork for future studies to evaluate CBD's impact on OUD&#xD;
      treatment outcomes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>The study is a double-blind, placebo-controlled, cross-over trial.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>This is a double-blind cross-over trial, in which the research staff and participants will be blinded.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Delayed discount</measure>
    <time_frame>Visit 2 and 3 (at least 1 week apart)</time_frame>
    <description>Monetary Choice Questionnaire will be used to calculate the rate of discounting.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Decision making</measure>
    <time_frame>Visit 2 and 3 (at least 1 week apart)</time_frame>
    <description>Iowa Gambling Task will be used to assess decision-making.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Attentional bias</measure>
    <time_frame>Visit 2 and 3 (at least 1 week apart)</time_frame>
    <description>Visual probe task will be used to assess attentional bias to drug-related cues.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Stress-reactivity</measure>
    <time_frame>Visit 2 and 3 (at least 1 week apart)</time_frame>
    <description>Physiologic and subjective stress will be assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Cue-reactivity</measure>
    <time_frame>Visit 2 and 3 (at least 1 week apart)</time_frame>
    <description>Cue-induced cravings will be assessed in response to drug-related ad neutral cues.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Opioid-use Disorder</condition>
  <arm_group>
    <arm_group_label>Cannabidiol 600mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects will receive 600mg of oral cannabidiol in a double-blind fashion. Cannabidiol will be provided using Epidiolexâ„¢ oral solution 100mg/mL. Following administration, a battery of tests will be conducted to examine reward- and stress-related neurocognitive processes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>All subjects will receive a matching placebo in a double-blind fashion. Following administration, a battery of tests will be conducted to examine the impact on reward- and stress-related neurocognitive processes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cannabidiol 100 MG/ML [Epidiolex]</intervention_name>
    <description>600mg</description>
    <arm_group_label>Cannabidiol 600mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  English speaking&#xD;
&#xD;
          -  DSM5 diagnosis of opioid use disorder&#xD;
&#xD;
          -  Receiving buprenorphine or methadone for treatment of opioid use disorder&#xD;
&#xD;
          -  Agreeable to abstaining from using any cannabis or CBD products for the duration of&#xD;
             the trial.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any self-reported use of cannabis or CBD products in the past 30 days&#xD;
&#xD;
          -  Baseline depression (PHQ9) or anxiety (GAD7) scores of greater than 10&#xD;
&#xD;
          -  Currently pregnant&#xD;
&#xD;
          -  Hepatic liver enzymes greater than 3x upper normal limit&#xD;
&#xD;
          -  Hypersensitivity to cannabinoids or sesame oil (CBD solution comes in sesame oil&#xD;
             emulsion)&#xD;
&#xD;
          -  Currently taking any medications with known significant pharmacokinetic interactions&#xD;
             with CBD&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 19, 2021</study_first_submitted>
  <study_first_submitted_qc>July 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 29, 2021</study_first_posted>
  <last_update_submitted>July 19, 2021</last_update_submitted>
  <last_update_submitted_qc>July 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Joji Suzuki, MD</investigator_full_name>
    <investigator_title>Director, Division of Addiction Psychiatry</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Opioid-Related Disorders</mesh_term>
    <mesh_term>Substance-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cannabidiol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

